| Literature DB >> 21870828 |
Li-Xing Zhao1, Sheng-Xiong Huang, Shu-Kun Tang, Cheng-Lin Jiang, Yanwen Duan, John A Beutler, Curtis J Henrich, James B McMahon, Tobias Schmid, Johanna S Blees, Nancy H Colburn, Scott R Rajski, Ben Shen.
Abstract
Our current natural product program utilizes new actinomycetes originating from unexplored and underexplored ecological niches, employing cytotoxicity against a selected panel of cancer cell lines as the preliminary screen to identify hit strains for natural product dereplication, followed by mechanism-based assays of the purified natural products to discover potential anticancer drug leads. Three new linear polyketides, actinopolysporins A (1), B (2), and C (3), along with the known antineoplastic antibiotic tubercidin (4), were isolated from the halophilic actinomycete Actinopolyspora erythraea YIM 90600, and the structures of the new compounds were elucidated on the basis of spectroscopic data interpretation. All four compounds were assayed for their ability to stabilize the tumor suppressor programmed cell death protein 4 (Pdcd4), which is known to antagonize critical events in oncogenic pathways. Only 4 significantly inhibited proteasomal degradation of a model Pdcd4-luciferase fusion protein, with an IC50 of 0.88±0.09 μM, unveiling a novel biological activity for this well-studied natural product.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21870828 PMCID: PMC3179765 DOI: 10.1021/np200603g
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050